Lose 15-20% of your body weight with branded GLP-1 medication, if prescribed.
Start Now
Fill out our simple online form about you health goals and medical history from the comfort of your home.
One of our leading doctors will review your form and determine if prescriptive treatment is right for you.
If prescribed your treatment will be shipped directly to you within 1-2 business days from our closest pharmacy hub.
KYO has partnered with state-licensed compounding pharmacies to offer compounded semaglutide that uses the same active ingredient as Ozempic and Wegovy. Compounding is the process of creating a medication that’s tailored to the needs of an individual patient. For example, some patients may need a medication in liquid form when the FDA-approved drug comes in a pill. Additionally, a pharmacy can compound medications of FDA-approved drugs that are in shortage. Compounded drugs are prepared by state-licensed compounding pharmacies that meet FDA and state requirements, including quality standards. When compounding in compliance with federal law, compounded drugs are not subject to FDA approval and do not have to undergo safety, effectiveness, or manufacturing review. Compounding is regulated by both FDA and state boards of pharmacy. A licensed compounding pharmacy must comply with both federal and state laws, which include administrative requirements and quality standards.
Yes, Ozempic and semaglutide are the same medication, but with different brand names. Semaglutide is the medication itself, while Ozempic is a brand name for semaglutide used specifically for treating type 2 diabetes through weekly injections. So, while semaglutide refers to the drug, Ozempic is one particular way that semaglutide is marketed and prescribed. There are other brands of semaglutide, like Wegovy for weight loss and Rybelsus for oral diabetes treatment.
Semaglutide mimics a hormone called GLP-1 (glucagon-like peptide-1), which regulates insulin secretion, slows digestion, and reduces appetite. This helps improve blood sugar control and can lead to weight loss.
Semaglutide is given as a subcutaneous injection (under the skin) once a week. It comes in a vial and can be self-administered in areas such as the stomach, thigh, or upper arm.
Semaglutide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not recommended for people with a history of pancreatitis. Always consult with a healthcare provider before starting any new medication.